货号:A667449 同义名: NSC 39069;Treosulphan
Treosulfan is an alkylating agent used for conventional, as well as high-dose chemotherapy regimens, whereby plasma concentrations over 500 μg/mL can be achieved.
There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.
Type | HazMat fee for 500 gram (Estimated) |
Excepted Quantity | USD 0.00 |
Limited Quantity | USD 15-60 |
Inaccessible (Haz class 6.1), Domestic | USD 80+ |
Inaccessible (Haz class 6.1), International | USD 150+ |
Accessible (Haz class 3, 4, 5 or 8), Domestic | USD 100+ |
Accessible (Haz class 3, 4, 5 or 8), International | USD 200+ |
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
描述 | Treosulfan, an alkylating agent, exhibits inhibitory activity against various cancer cell lines, including Panc-1, Miapaca-2, and Capan-2 cells, with IC50 values of 3.6 µg/mL, 1.8 µg/mL, and 2.1 µg/mL, respectively. At a concentration of 100 µg/mL, Treosulfan shows nearly complete cytotoxicity against these cell lines. Its combination with LY 188011 enhances anti-cancer activity, whereas combining Treosulfan with 5-FU results in an antagonistic effect on Panc-1 and Miapaca-2 cells at various concentrations[1]. Furthermore, at 800 µg/mL, Treosulfan significantly affects erythrocyte morphology, increases annexin-V binding, intracellular calcium ([Ca2+].i), and reactive oxygen species (ROS) levels. The removal of extracellular Ca2+ neutralizes Treosulfan's effect on annexin-V binding[2]. |
体内研究 | At a dose of 1.5 g/kg/day, Treosulfan induces rapid myeloablation and depletes splenic B and T cells in mice. This dose also transiently stimulates interleukin-2 production in spleen cells without significantly affecting the synthesis of tumor necrosis factor-alpha (TNF-α) and/or interferon-gamma (IFN-γ)[3]. |
体外研究 | Treosulfan, an alkylating agent, exhibits inhibitory activity against various cancer cell lines, including Panc-1, Miapaca-2, and Capan-2 cells, with IC50 values of 3.6 µg/mL, 1.8 µg/mL, and 2.1 µg/mL, respectively. At a concentration of 100 µg/mL, Treosulfan shows nearly complete cytotoxicity against these cell lines. Its combination with LY 188011 enhances anti-cancer activity, whereas combining Treosulfan with 5-FU results in an antagonistic effect on Panc-1 and Miapaca-2 cells at various concentrations[1]. Furthermore, at 800 µg/mL, Treosulfan significantly affects erythrocyte morphology, increases annexin-V binding, intracellular calcium ([Ca2+].i), and reactive oxygen species (ROS) levels. The removal of extracellular Ca2+ neutralizes Treosulfan's effect on annexin-V binding[2]. |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT00427999 | Prostate Cancer | Phase 2 | Completed | - | Germany ... 展开 >> Novartis Investigative Site Bad Reichenhall, Germany, 83435 Novartis Investigative Site Bonn, Germany, 53105 Novartis Investigative Site Hamburg, Germany, 20246 Novartis Investigative Site Hamburg, Germany, 22607 Novartis Investigative Site Kassel, Germany, 34131 Novartis Investigative Site Markkleeberg, Germany, 04416 Novartis Investigative Site Passau, Germany, 94032 Novartis Investigative Site Planegg, Germany, 82152 Novartis Investigative Site Regensburg, Germany, 93053 Novartis Investigative Site Tübingen, Germany, 72076 收起 << |
NCT01423500 | Lymphoblastic Leukemia, Acute,... 展开 >> Childhood; 收起 << | Phase 3 | Unknown | September 2016 | Austria ... 展开 >> Universitätsklinik für Kinder- und Jugendheilkunde, Klin. Abt. f. Hämato-Onkologie Graz, Austria, 8036 Universitätsklinik für Kinder- und Jugendheilkunde Innsbruck, Austria, 6020 St. Anna Children's Hospital Vienna, Austria, A-1090 Czech Republic Department of Paediatric Haematology and Oncology HSCT-Unit Prague, Czech Republic, 15006 Denmark Pediatric Clinic II, Rigshospitalet Copenhagen, Denmark, 4074 France Pediatric Immuno-Hematology Unit Robert Debré Hospital Paris, France, 75935 Israel Rambam Medical Center Haifa, Israel, 31096 Schneider Children`s Medical Center of Israel Petach-Tikva, Israel, 49202 Italy Clinica Pediatrica dell`Universita di Milano Bicocca, Hospitale San Gerardo Monza, Italy, 20052 Netherlands Leiden University Hospital Leiden, Netherlands, 2300 Radboud University - Nijmegen Medical Centre Nijmegen, Netherlands, 6500 Department of Paediatric Haematology and Oncology, Wilhelmina Children's Hospital Utrecht, Netherlands, 3584 Poland University Hospital, Collegium Medicum UMK, Pediatric Hematology and Oncology Bydgoszcz, Poland, 85-094 Department of Transplantation, University Children's Hospital Cracow, Poland, 30-663 Children`s University Hospital - Hematology - Oncology Lublin, Poland, 20-093 Department of Pediadric Oncology, Hematology and Transplantology, University of Medical Sciences Poznan, Poland, 60-572 Wroclaw Medical University, Dept. of Children Hematology and Oncology Wroclaw, Poland, 50-345 Slovakia Department of Pediatric Bone Marrow Transplantation Unit, University Childrens´ Hospital Bratislava, Slovakia, 833 40 Sweden Department of Pediatric Oncology, Lund University Hospital Lund, Sweden, 221-85 Turkey Department of Pediatrics, Gülhane Military Medical Academy Ankara, Turkey, 06018 Dept. of Paediatrics - BMT Unit, School of Medicine, University of Ankara Ankara, Turkey, 06100 Department of Pediatric Hematology-Oncology and Pediatric Stem Cell Transplantation, Akdeniz University School of Medicine Antalya, Turkey, 07070 Department of Pediatric Hematology, Oncology and BMT, Istanbul School of Medicine Istanbul, Turkey, 343990 Pediatric BMT Centre, Ege University Izmir, Turkey, 35100 收起 << |
NCT01949129 | Acute Lymphoblastic Leukaemia | Phase 2 Phase 3 | Recruiting | April 2023 | - |
计算器 | ||||
存储液制备 | 1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
3.59mL 0.72mL 0.36mL |
17.97mL 3.59mL 1.80mL |
35.93mL 7.19mL 3.59mL |
CAS号 | 299-75-2 |
分子式 | C6H14O8S2 |
分子量 | 278.301 |
别名 | NSC 39069;Treosulphan;(2S,3S)-2,3-Dihydroxybutane-1,4diyl dimethanesulfonate. |
运输 | 蓝冰 |
存储条件 |
液体 -20°C:3-6个月-80°C:12个月 粉末 Sealed in dry,Store in freezer, under -20°C |
溶解度 |
DMSO: 105 mg/mL(377.29 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO H2O: 50 mg/mL(179.66 mM),配合低频超声助溶 |
动物实验配方 |